Table 2.
Clinical characteristics of patients with and without severe SAS
| Parameter | AHI >30 | AHI ≤30 | p value |
|---|---|---|---|
| Age, years | 73.4 ± 10.4 | 70.2 ± 9.5 | 0.10175 |
| Male, % | 87.8 | 85.5 | 0.73421 |
| BMI | 23.8 ± 3.9 | 24.2 ± 4.0 | 0.56466 |
| Systolic blood pressure, mm Hg | 131.9 ± 22.4 | 135.7 ± 20.9 | 0.36088 |
| Diastolic blood pressure, mm Hg | 73.2 ± 15.6 | 73.9 ± 12.0 | 0.78003 |
| History of CVD, % | 41.5 | 47.8 | 0.51697 |
| History of DM, % | 58.5 | 55.1 | 0.72316 |
| History of hypertension, % | 97.6 | 97.1 | 0.88623 |
| Angiotensin II receptor blocker, % | 73.1 | 71.0 | 0.80796 |
| Angiotensin converting enzyme inhibitor, % | 4.9 | 11.6 | 0.23611 |
| Calcium channel blocker, % | 78.0 | 69.1 | 0.33404 |
| β-Blocker, % | 31.7 | 29.0 | 0.76333 |
| Loop diuretics, % | 36.6 | 29.0 | 0.40797 |
| ESA, % | 36.6 | 17.4 | 0.02371 |
| Vitamin D receptor activator, % | 4.9 | 10.1 | 0.32981 |
| Statin, % | 51.2 | 55.0 | 0.69519 |
| NaHCO3, % | 19.5 | 18.8 | 0.95965 |
| White blood cells, /μl | 6,251.2 ± 1,636.2 | 6,220.3 ± 1,689.6 | 0.92535 |
| Hemoglobin, g/dl | 11.1 ± 1.9 | 11.4 ± 1.5 | 0.37400 |
| Albumin, g/dl | 3.8 ± 0.5 | 3.9 ± 0.5 | 0.37216 |
| Alanine transaminase, U/l | 16.6 ± 15.1 | 18.2 ± 12.0 | 0.52631 |
| Alkaline phosphatase, U/l | 246.1 ± 77.0 | 236.2 ± 77.0 | 0.51387 |
| Uric acid, mg/dl | 7.1 ± 1.7 | 7.2 ± 1.9 | 0.86089 |
| Blood urea nitrogen, mg/dl | 44.3 ± 17.0 | 42.8 ± 15.8 | 0.63909 |
| Creatinine, mg/dl | 3.2 ± 1.3 | 3.1 ± 1.4 | 0.72728 |
| eGFR, ml/min/m2 | 19.2 ± 9.5 | 20.2 ± 9.8 | 0.58407 |
| Na, mEq/l | 138.9 ± 3.0 | 138.8 ± 2.5 | 0.78026 |
| K, mEq/l | 4.8 ± 0.6 | 4.7 ± 0.6 | 0.57355 |
| Adjusted Ca, mg/dl | 9.2 ± 0.5 | 9.3 ± 0.6 | 0.67205 |
| P, mg/dl | 3.9 ± 1.0 | 3.9 ± 0.8 | 0.92155 |
| C-reactive protein, mg/dl | 0.32 ± 0.35 | 0.42 ± 0.70 | 0.39543 |
| LDL-C, mg/dl | 101.6 ± 40.6 | 88.38 ± 30.0 | 0.05310 |
| HDL-C, mg/dl | 42.39 ± 9.9 | 44.4 ± 11.5 | 0.33099 |
| Triglyceride, mg/dl | 146.2 ± 81.7 | 182.3 ± 198.4 | 0.27131 |
| Intact parathyroid hormone, pg/ml | 167.3 ± 107.9 | 150.7 ± 107.4 | 0.43 |
| Brain natriuretic peptide, pg/ml | 216.6 ± 326.0 | 100.3 ± 135.7 | 0.01071 |
| pH | 7.360 ± 0.040 | 7.360 ± 0.040 | 0.79913 |
| HCO3−, mEq/l | 20.4 ± 2.7 | 20.5 ± 3.0 | 0.81865 |
| Cardiothoracic ratio, % | 52.8 ± 6.5 | 49.1 ± 5.7 | 0.00223 |
| Urinary protein, g/day | 1.6 ± 1.9 | 1.5 ± 1.7 | 0.68431 |
| Thoracic aortic calcification, % | 46.3 | 31.9 | 0.10477 |
| Abdominal aortic calcification, % | 55.6 | 67.2 | 0.24750 |
| Valve calcification, % | 48.8 | 37.7 | 0.25381 |
| Lower ABI | 1.08 ± 0.16 | 1.12 ± 0.13 | 0.23058 |
| Faster PWV, cm/s | 1,920.5 ± 522.5 | 1,902.9 ± 380.6 | 0.84400 |
| IMTmax, mm | 2.82 ± 1.07 | 2.68 ± 1.49 | 0.58825 |
| PS | 12.8 ± 5.96 | 9.38 ± 5.47 | 0.00265 |
eGFR = Estimated glomerular filtration rate.